Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.

Learning Disabilities

Learning Disabilities

Learning disabilities are cognitive disorders caused by neurological impairments that affect cognitive functions like language and reading, without indicating overall intellectual or developmental challenges. These disabilities differ from global intellectual or developmental disabilities as they are limited to distinct cognitive functions. Common learning disabilities include dysgraphia, dyslexia, and dyscalculia, each of which impacts unique aspects of learning.
Dyslexia
Dyslexia is a...

Adrenergic Agonists: Mixed-Action Agents

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Untangling the Confusion: A Scoping Review of Terminology and Assessment Methods for Acute Confusional States Following Traumatic Brain Injury.

The Journal of head trauma rehabilitation·2026

Same author

Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis.

BMJ (Clinical research ed.)·2026

Same author

Direct-to-Participant Enrollment in a Virtual Trial: Lessons Learned From the Heartline Study.

JACC. Advances·2026

Same author

A survey of stress ulcer prophylaxis practice patterns for critically ill patients before and after participating in a randomised controlled trial.

Australian critical care : official journal of the Confederation of Australian Critical Care Nurses·2026

Same author

Anti-Xa Levels With Venous Thromboembolism Prophylaxis in Critical Care: A Systematic Review and Meta-Analysis.

Critical care medicine·2026

Same author

Population pharmacokinetic modeling of piperacillin in critically ill adult patients: consideration of sex-based differences during model development.

Expert review of clinical pharmacology·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Methylphenidate in children with ADHD with or without learning disability.

David Williamson¹, Desiree W Murray, C V Damaraju

¹1Janssen Scientific Affairs, LLC, Raritan, NJ, USA.

Journal of Attention Disorders

|May 26, 2012

Summary

This summary is machine-generated.

Osmotic Release Oral System (OROS) methylphenidate improved ADHD symptoms and cognitive performance in children with and without learning disabilities. This ADHD treatment demonstrated significant benefits in academic tasks and classroom behavior.

Keywords:

ADHD OROS methylphenidate behavior cognitive skills learning disability

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Related Experiment Videos

Last Updated: May 22, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Area of Science:

Pediatric Psychiatry
Neurodevelopmental Disorders
Pharmacological Treatments

Background:

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder in children.
Comorbid learning disabilities (LD) frequently occur in children with ADHD, complicating treatment.
Osmotic Release Oral System (OROS) methylphenidate is a long-acting formulation used for ADHD management.

Purpose of the Study:

To evaluate the efficacy of OROS methylphenidate in children with ADHD.
To compare treatment response in children with ADHD with and without comorbid learning disabilities (LD).

Main Methods:

Analysis of data from two 6-week, double-blind, randomized, placebo-controlled, crossover studies.
Inclusion of 135 children (ages 9-12) with ADHD, with or without LD (reading, math, or both).
Assessment using cognitive tests, academic tasks, and observed classroom behavior during OROS methylphenidate and placebo treatment phases.

Main Results:

OROS methylphenidate significantly improved ADHD Rating Scale scores in both ADHD with and without LD groups.
Participants showed enhanced performance on cognitive measures (e.g., Test of Variables of Attention) during OROS methylphenidate treatment.
Academic-related tasks and observed classroom behavior also improved with OROS methylphenidate compared to placebo.

Conclusions:

OROS methylphenidate treatment led to improvements in behavior and performance for children with ADHD.
The findings support the use of OROS methylphenidate in managing ADHD symptoms, even in the presence of comorbid learning disabilities.